ArticlePathogens (Basel, Switzerland)2026
Comparing Self-Administered Outpatient Parenteral Antimicrobial Therapy (S-OPAT) with Alternative Delivery Models: Risk Factors for Treatment Failure and Complications in a UK Cohort.
Article in Pathogens (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Self-administered outpatient parenteral antimicrobial therapy (S-OPAT) is an increasingly recognised antimicrobial delivery model, yet comparative evidence on its safety and effectiveness remains limited. We compared clinical outcomes across OPAT delivery models and examined predictors of adverse outcomes in S-OPAT. Adult OPAT episodes at a large UK teaching hospital (January 2023-January 2026) were categorised as S-OPAT, healthcare professional home-administered (H-OPAT), or clinic-based (C-OPAT). Primary outcomes were treatment failure, complications, and 30-day unplanned hospitalisation. Outcome risks were compared using robust multivariable Poisson regression with generalised estimating equations and Bonferroni correction. Among 1064 OPAT episodes, 286 (26.9%) were S-OPAT, and cure/clinical improvement occurred in 912/1064 (85.7%). Treatment failure occurred in 26/286 (9.1%) S-OPAT episodes, with no significantly higher risk than H-OPAT (adjusted relative risk [aRR], 0.72; 98.3% CI, 0.43-1.19) or C-OPAT (aRR, 0.94; CI 0.48-1.84). Rates of unplanned hospitalisation and OPAT-related complications were broadly comparable, except potentially vascular access-related events. Within S-OPAT, older age, higher comorbidity burden, diabetes, peripheral vascular disease, and central venous access were associated with treatment failure. Overall, these findings suggest that S-OPAT can be delivered safely and effectively to appropriately selected patients, while enhanced monitoring may be warranted for older individuals and those with greater comorbidity burden or central venous access devices.
Indexed as
Identifiers
42796749What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.